Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Pfizer terminated NMIBC trial due to strategic consideration

<< Previous

Bullboard Posts

Next >>

Comment by plantraderon Dec 22, 2022 12:54pm

194 Views

Post# 35187427

RE:RE:RE:Pfizer terminated NMIBC trial due to strategic consideration

ScienceFirst wrote: PlanTreader ... Be careful for what you're wishing for. You might get it ... lolll

________________________

plantrader - (12/22/2022 11:52:09 AM)

RE:Pfizer terminated NMIBC trial due to strategic consideration

ScienceFirst wrote:Interesting ... Pfizer has decided to terminate Study C4661001 due to strategic considerations

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

ClinicalTrials.gov Identifier: NCT05259397

Recruitment Status  : Withdrawn (Pfizer has decided to terminate Study C4661001 due to strategic considerations. This decision is not due to any specific safety reasons or requests from any regulatory authorities. No participants have been enrolled in this study.)
First Posted  : February 28, 2022

Last Update Posted  : October 24, 2022

They forgot the part about the reason being due to having deciced to acquire Theralase for $10B USD. How could they leave that part out? lol